What question did this study set out to answer?

This research aims to evaluate the efficacy and safety of AGX101, a TM4SF1-directed tubulin inhibitor, in combination with immune checkpoint inhibitors.

April 5, 2026Cancer Research

In Vivo Results of AGX101, a TM4SF1-Directed Tubulin Inhibitor with Immune Checkpoint Inhibitors

View Full Paper

Ask AI

Bookmark

Authors

SJShou-Ching JaminetAngiogenesis Foundation PJPaul JaminetAngiogenesis Foundation GWGlen J. WeissAngiogenesis Foundation

Discussion

Member takes

Implication

Efficacy of AGX101 in enhancing therapeutic response in tumors, highlighting its potential benefits with immune checkpoint inhibitors.

Key Points

This research aims to evaluate the efficacy and safety of AGX101, a TM4SF1-directed tubulin inhibitor, in combination with immune checkpoint inhibitors.
Assessed TM4SF1 expression using immunohistochemistry.
Evaluated safety and pharmacokinetics in non-human primates.
Conducted efficacy studies in mouse models to determine the minimum effective dose (MED).
Calculated therapeutic index (TI) based on HNSTD and MED.
Investigated synergy with immune checkpoint inhibitors.
AGX101 showed a favorable safety profile in non-human primates.
In mouse models, AGX101 demonstrated robust efficacy through three mechanisms of action.
High response rates were observed; CT26 showed 71% RR with AGXB01+anti-CTLA-4 vs 13% for anti-CTLA-4 alone.
In Renca models, 80% RR was noted with AGXB01+anti-CTLA-4 vs 20% for the latter alone.
Durable immune responses were seen, with 38 of 39 rechallenged mice successfully eradicating new tumors.

Cite This Study

Jaminet et al. (2026) studied this question.

synapsesocial.com/papers/69d1fd4ea79560c99a0a3454 https://doi.org/10.1158/1538-7445.am2026-3798

View Full Paper

Ask AI

Bookmark

In Vivo Results of AGX101, a TM4SF1-Directed Tubulin Inhibitor with Immune Checkpoint Inhibitors

Discussion

Member takes

Implication

Key Points

Cite This Study

In Vivo Results of AGX101, a TM4SF1-Directed Tubulin Inhibitor with Immune Checkpoint Inhibitors

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider